DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients

Table 2 Wald tests for models with GBM classification and study origin, and interaction

Characteristic	MES	RTK I	RTK II	GBM classification		Study		GBM Class x Study
Characteristic	Mean (sd)	Mean (sd)	Mean (sd)	*F-value	Pr(> F)	*F-value	Pr(> F)	*F-value	Pr(> F)
Patient age [yrs]	60.175 (10.853)	61.075 (11.927)	60.834 (10.83)	0.216	0.806	52.158	< 0.001	0.747	0.612
DNAm age [yrs]	89.246 (21.746)	94.538 (24.999)	104.106 (26.163)	10.717	< 0.001	4.670	0.003	1.896	0.079
Age accel [yrs]	29.072 (19.566)	33.463 (21.956)	43.273 (25.652)	10.480	< 0.001	1.457	0.225	2.456	0.024
HM-purity	0.592 (0.104)	0.817 (0.105)	0.802 (0.099)	68.162	< 0.001	2.288	0.078	1.086	0.369
Global HME	0.556 (0.029)	0.571 (0.027)	0.545 (0.029)	18.557	< 0.001	0.029	0.994	0.394	0.883
HME prom CpG	0.362 (0.032)	0.361 (0.03)	0.363 (0.029)	0.086	0.917	0.147	0.932	1.815	0.094

^*F-values are computed with covariance matrix, estimated by sandwich estimation (type HC3) to reduce the effect of the variance heterogeneity

ISSN: 2051-5960